Association between Serum Growth Hormone Levels and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Xu, Lei ^a,b   Xu, Chengfu ^b   Yu, Chaohui ^b   Miao, Min ^c   Zhang, Xuequn ^b   Zhu, Zhongwei ^c   Ding, Xiaoyun ^a   Li, Youming ^b  

^a NINGBO FIRST HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c Zhenhai Lianhua Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; GROWTH RETARDATION; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PREVALENCE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; CHINA; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HUMAN GROWTH HORMONE; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE;

EID: 84865615153     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044136     Document Type: Article

References (28)

1. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, et al. (1999) Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107: 450-455.
2. Marchesini G, Marzocchi R, Agostini F, Bugianesi E, (2005) Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16: 421-427.
3. Hong JW, Kim JY, Kim YE, Lee EJ, (2011) Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men. Horm Metab Res 43: 48-54.
4. Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, et al. (2010) Prevalence of metabolic syndrome in adult hypopituitary growth hormone(GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab 95: 74-81.
5. Di SC, Pivonello R, Pizza G, De Rosa A, Lombardi G, et al. (2010) Prevalence of the metabolic syndrome in moderately-severely obese subjects withand without growth hormone deficiency. J Endocrinol Invest 33: 171-177.
6. Pasarica M, Zachwieja JJ, Dejonge L, Redman S, Smith SR, (2007) Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity. J Clin Endocrinol Metab 92: 4265-4270.
7. Follin C, Thilen U, Ahren B, Erfurth EM, (2006) Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia. J Clin Endocrinol Metab 91: 1872-1875.
8. Ichikawa T, Hamasaki K, Ishikawa H, Ejima E, Eguchi K, et al. (2003) Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut 52: 914.
9. Ichikawa T, Nakao K, Hamasaki K, Furukawa R, Tsuruta S, et al. (2007) Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int 1: 287-294.
10. Adams LA, Feldstein A, Lindor KD, Angulo P, (2004) Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39: 909-914.
11. Gardner CJ, Irwin A, Daousi C, Macfarlane I, Joseph F, et al. (2012) Non Alcoholic Fatty Liver Disease, growth hormone deficiency and the effects of growth hormone replacement: a LIVERpool magnetic resonance spectroscopy study. Eur J Endocrinol 166: 993-1002.
12. Li Y, Xu C, Yu C, Xu L, Miao M, (2009) Association of serum uric acid level with non-alcoholic fatty liver disease: across-sectional study. J Hepatol 50: 1029-1034.
13. Targher G, Bertolini L, Poli F, Rodella S, Scala L, et al. (2005) Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54: 3541-3546.
14. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, et al. (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42: 44-52.
15. Cerda C, Perez-Ayuso RM, Riquelme A, Soza A, Villaseca P, et al. (2007) Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 47: 412-417.
16. Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, et al. (2007) What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific. J Gastroenterol Hepatol 22: 794-800.
17. Johannsson G, Bengtsson BA, (1999) Growth hormone and the metabolic syndrome. J Endocrinol Invest 22: 41-46.
18. Fusco A, Miele L, D'Uonnolo A, Forgione A, Riccardi L, et al. (2011) Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels. Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2011.04291.x.
19. Melmed S, (1984) Insulin suppresses growth hormone secretion by rat pituitary cells. J Clin Invest 73: 1425-1433.
20. Misra M, Bredella MA, Tsai P, Mendes N, Miller KK, et al. (2008) Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls. Am J Physiol Endocrinol Metab 295: E385-E392.
21. Tarantino G, Savastano S, Colao A, (2010) Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol 16: 4773-4783.
22. Lanes R, Paoli M, Carrillo E, Villaroel O, Palacios A, (2004) Peripheral inflammatory and fibrinolytic markers in adolescents with growth hormone deficiency: relation to postprandial dyslipidemia. J Pediatr 145: 657-661.
23. Utz AL, Yamamoto A, Hemphill L, Miller KK, (2008) Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. J Clin Endocrinol Metab 93: 2507-2514.
24. Gambino R, Musso G, Cassader M, (2011) Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal 15: 1325-1365.
25. Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, et al. (2007) Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology 132: 938-943.
26. Ungvari Z, Sosnowska D, Podlutsky A, Koncz P, Sonntag WE, et al. (2011) Free radical production, antioxidant capacity, and oxidative stress response signatures in fibroblasts from Lewis dwarf rats: effects of life span-extending peripubertal GH treatment. J Gerontol A Biol Sci Med Sci 66: 501-510.
27. Qin Y, Tian YP, (2010) Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. Lipids Health Dis 9: 78.
28. Angulo P, (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231.